Reviewing INmune Bio (NASDAQ:INMB) & Natera (NASDAQ:NTRA)

INmune Bio (NASDAQ:INMB) and Natera (NASDAQ:NTRA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Insider and Institutional Ownership

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 21.4% of INmune Bio shares are held by company insiders. Comparatively, 5.1% of Natera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares INmune Bio and Natera’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Natera	-7.11%	-11.38%	-7.87%

Earnings and Valuation

This table compares INmune Bio and Natera”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50,000.00	906.31	-$45.93 million	($0.67)	-2.44
Natera	$2.71 billion	20.96	-$208.16 million	($1.36)	-289.49

INmune Bio has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for INmune Bio and Natera, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1	0	0	1	2.50
Natera	1	4	16	2	2.83

Natera has a consensus price target of $368.69, indicating a potential downside of 6.36%. Given Natera’s stronger consensus rating and higher probable upside, analysts clearly believe Natera is more favorable than INmune Bio.

Risk & Volatility

INmune Bio has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Natera has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.

Summary

Natera beats INmune Bio on 9 of the 15 factors compared between the two stocks.

About INmune Bio

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

About Natera

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.